Skip to content

A randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of Qilin Pill on pregnancy outcomes in patients undergoing in vitro fertilization-embryo transfer

A randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of Qilin Pill on pregnancy outcomes in patients undergoing in vitro fertilization-embryo transfer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027111
Enrollment
Unknown
Registered
2019-11-01
Start date
2019-11-05
Completion date
Unknown
Last updated
2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Sponsors

Affiliated Hospital of Shaanxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 42 Years

Inclusion criteria

Inclusion criteria: 1. Patients who are willing to take oral medications of traditional Chinese medicine (TCM) and sign the informed consent form; 2. In line with both the western diagnostic criteria and indications of IVF-ET set by National Health Commission of the People's Republic of China; 3. Infertility with liver-stagnation and kidney-deficiency according to TCM syndrome differentiation standard; 4. Aged 25 to 42; 5. Basal follicle stimulating hormone (bFSH) = 8; 7. Chinese citizens; 8. Assisted reproduction with IVF-ET (long protocol or ultra-long protocol).

Exclusion criteria

Exclusion criteria: 1. Adenomyosis or uterine fibroids compressing the uterine cavity line; 2. Untreated hydrosalpinx; 3. Endometrial diseases being not cured; 4. Frozen embryo transplantation; 5. Treatment of TCM for infertility within 3 months; 6. Patients who are participating or have participated in other clinical trials of TCM within one month; 7. Contraindications to assisted reproductive technology; 8. Severe anatomical abnormalities of the reproductive tract; 9. Repeated implantation failure (RIF, failure to clinical pregnancy after transfer in three or more IVF treatment cycles, with cumulative transfer of at least four cleavage-stage high-quality embryos or three high-quality blastocysts).

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate;live birth rate;

Countries

China

Contacts

Public ContactHe Fengjie

Affiliated Hospital of Shaanxi University of Chinese Medicine

hefengjie2013@163.com+86 13892908898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026